What is Mesoblast?
Founded in 2004 and headquartered in Melbourne, Victoria, Australia, Mesoblast is a prominent biopharmaceutical firm dedicated to the creation and commercialization of allogeneic cellular medicines. The company's therapeutic pipeline spans critical areas including cardiovascular diseases, spine orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory conditions. Mesoblast's innovative approach leverages cutting-edge cell therapy to address unmet medical needs across a broad spectrum of serious health challenges.
How much funding has Mesoblast raised?
Mesoblast has raised a total of $744.3M across 8 funding rounds:
Stock Offering
$68.3M
Share Placement
$40M
Debt
$75M
Share Placement
$51M
Share Placement
$90M
Corporate Investment
$110M
Share Placement
$260M
Stock/Share Issuance
$50M
Stock Issuance/Offering (2015): $68.3M with participation from Undisclosed
Share Placement (2017): $40M led by Undisclosed
Debt (2018): $75M supported by Hercules Capital
Share Placement (2019): $51M featuring Undisclosed
Share Placement (2020): $90M backed by Undisclosed
Corporate Investment (2021): $110M with participation from Surgcenter
Share Placement (2025): $260M, investors not publicly disclosed
Stock/Share Issuance (2025): $50M, investors not publicly disclosed
Key Investors in Mesoblast
Hercules Capital
Hercules Capital is a specialty finance company that provides venture growth loans to high-growth, innovative venture capital-backed companies, particularly in the technology and life sciences sectors.
Surgcenter
Surgcenter appears to be an entity involved in strategic corporate investments, potentially focusing on companies within the healthcare or biopharmaceutical industry.
Undisclosed Investors
What's next for Mesoblast?
The recent major strategic investment signals Mesoblast's readiness to accelerate its commercialization efforts and potentially expand its clinical development programs. This infusion of capital is expected to bolster its efforts in bringing its advanced cellular therapies to market, particularly in its key focus areas. The company's trajectory suggests a continued emphasis on strategic partnerships and further funding rounds to support its long-term growth objectives and solidify its market presence in the regenerative medicine landscape.
See full Mesoblast company page
